New hope for kids with deadly brain tumors: trial tests Immune-Boosting drug
NCT ID NCT04049669
Summary
This study is testing whether adding an immunotherapy drug called indoximod to standard chemotherapy and radiation can better control aggressive brain tumors in children and young adults. It is for patients aged 3 to 21 with specific types of progressive brain cancer or newly diagnosed DIPG. The goal is to see if blocking a natural immune-suppressing pathway helps the body's own defenses fight the tumor more effectively alongside standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Augusta University, Georgia Cancer Center
Augusta, Georgia, 30912, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University, Children's Heathcare of Atlanta
Druid Hills, Georgia, 30322, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.